Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 OCT 19 ... gene in their cancers, which suggests that common oral EGFR inhibitor drugs, such as Tarceva® (erlotinib), are unlikely to yield dramatic remissions. Additionally, cancer ...
2009 AUG 17 ... multi-center Phase 2b clinical trial comparing pralatrexate and erlotinib (Tarceva®), both with vitamin B12 and folic acid supplementation, in patients with Stage ...
2009 NOV 16 ... international, multi-center clinical trial comparing pralatrexate and erlotinib (Tarceva®) in patients with Stage IIIB/IV non-small cell lung cancer (NSCLC) who are, or ...
2009 NOV 23 ... tenure Pfizer discovered and/or developed a number of important new medicines including Tarceva, Chantix, Zoloft (PTSD), Selzentry and Lyrica along with a number of other medicines ...
2009 AUG 17 ... for the Study of Lung Cancer. Both cetuximab (Erbitux) and erlotinib (Tarceva) inhibit the epidermal growth factor receptor (EGFR) and the assumption has been that ...
2009 OCT 12 ... approved anti-cancer agents. Currently IMO-2055 is being evaluated in combination with Tarceva® and Avastin® in non-small cell lung cancer and in combination with ...
2009 OCT 5 ... trial evaluating IMO-2055, an agonist of Toll-like Receptor (TLR) 9, in combination with Tarceva® and Avastin® in patients with non-small cell lung cancer (NSCLC). The data ...
2009 AUG 17 ... Phase 1b Clinical Trial of IMO-2055 in Combination with Avastin® and Tarceva® in Non-small Cell Lung Cancer In this trial, IMO-2055 is being ...
2009 SEP 28 ... despite promising clinical data from maintenance use with drugs such as Alimta and Tarceva. "The disconnect between attitudes and behavior shows that there is a ...
2009 AUG 17 ... (NASDAQ: OSIP) announced further results from the Phase III SATURN study showing that Tarceva® (erlotinib) extended the survival of patients with advanced non-small cell lung ...
2009 AUG 3 ... which patients optimally benefit from therapy with the company's flagship product, Tarceva® (erlotinib). Because mesenchymal tumor cells co-opt different sets of oncogenic ...
2009 SEP 21 ... OSI intends to initiate a registration-oriented combination study of OSI-906 with Tarceva® (erlotinib) in NSCLC. Initial indications of monotherapy activity for OSI-906 in ...
2009 AUG 3 ... to revenues of $96 million for the second quarter of 2008. Total worldwide net sales of Tarceva for the three and six months ended June 30, 2009, as reported to the Company by its ...
2009 NOV 2 ... of 2008, an 18% increase over the prior year period. Total worldwide net sales of Tarceva for the three and nine months ended September 30, 2009, as reported to the Company by ...
2009 AUG 17 ... held in Orlando, Florida from May 29 through June 2. Highlights include data from the Tarceva and Alimta studies as maintenance therapy in first-line non-small cell lung cancer. ...
2009 JUL 27 ... were inhibited by treatment of cultured cells with the EGFR tyrosine kinase inhibitor, Tarceva (erlotinib). In a consecutive series of human lung tumor specimens, pEGFR protein levels ...
2009 NOV 23 ... eruption and progressive nonscarring alopecia shortly after initiation of erlotinib (Tarceva). Scalp biopsy showed near-equal number of anagen and catagen/telogen hair follicles, ...
2009 OCT 19 ... According to a study from Seoul, South Korea, "Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal growth factor receptor ...
2009 SEP 28 ... application for U.S. Patent No.5,747,498 (the '498) composition of matter patent for Tarceva® (erlotinib). The reissued patent will replace the original '498 patent and have ...
